Squamous carcinoma includes lung squamous carcinoma, esophageal squamous carcinoma, etc. Immunotherapy protocols vary. Commonly used drugs include pabolizumab, karelizumab, tirilizumab and so on. They are often combined with some chemotherapeutic drugs. 1. Lung squamous carcinoma: immunotherapy for lung squamous carcinoma is often used for patients with no driver gene in stage IV, and commonly used treatment programs include pabrolizumab single drug, paclitaxel + platinum + tirilizumab, gemcitabine + platinum + sindelizumab and so on. Atelizumab can also be chosen according to the condition. 2. Esophageal squamous carcinoma: Immunotherapy for esophageal squamous carcinoma is mainly used for patients with distant metastasis, and commonly used first-line treatment options include: pembrolizumab+fluorouracil chemotherapeutic drugs+cisplatin, carilizumab+paclitaxel+cisplatin, etc. Second-line treatment can also be used alone with pembrolizumab+platinum+tirilizumab. Second-line treatment can also use immunotherapeutic drugs such as pabrolizumab, nabulizumab, and karelizumab alone. In addition to the above cancers, squamous cancers also include cervical squamous cancer, bladder squamous cancer, head and neck squamous cancer, etc., with different immunotherapy protocols. It is recommended that patients go to the hospital as early as possible for consultation, so as to promptly clarify the specific pathological type and choose the appropriate treatment plan under the guidance of professional doctors.